text:
The All-State Utah High School Art Exhibition, part of the Utah Arts & Museums' Traveling Exhibition Program
The All-State Utah High School Art Exhibition
part of the Utah Arts & Museums' Traveling Exhibition Program
Reception:Thu, Jun 20, 6-7:30pm
The Utah Arts Festival and The City Library are showcasing Utah's top youth talent with the Traveling Exhibition of The All-State Utah Arts High School Exhibition. The exhibit is free to the public and features the award-winning artwork by students participating in the 2012 All-State High School Show. A reception for the artists and the public will launch the exhibit on Thursday, June 20, 6-7:30pm, coinciding with opening day of The Utah Arts Festival at Library Square.
For more information, call The Gallery at Library Square, 801-524-8200. For all the details about the 2013 Utah Arts Festival, June 20-23, go to uaf.org.
The exhibit, presented in partnership with the Utah Division of Arts & Museums and the Springville Museum of Art, is part of the Utah Arts & Museums' Traveling Exhibition Program. The competition, open to 11th- and 12th-grade students from schools throughout Utah, is sponsored each spring by the Springville Museum of Art. The show offers a professional forum for students to display their best work. For many participants, this contest provides a first taste of artistic competition, preparing them for the future competitions they may later enter.
Artwork is submitted by the school's art department; with mediums including drawing, opaque painting, transparent watercolor, sculpture, fiber, printmaking, jewelry, photography, ceramics, commercial and mixed media.
Daenen Rolapp, American Fork High School
Davin Sills, Bear River High School
Alysha Lloyd, Copper Hills High School
Hannah Buhler, Copper Hills High School
Adam Callister, Davis High School
Gabrielle Smith, Herriman High School
CJ Hellige, Hillcrest High School
Joohee Suh, Logan High School
Hyrum Siebers, Mountain Crest High School
Fiona Barney, Mountain View High School
Olivia Liston, Olympus High School
Nikki Frampton, Pine View High School
Ally Spencer, Riverton High School
Chelse Reynolds, Sky View High School
Jordan Carter, South Sevier High School
Chelsea Jones, Stansbury High School
Roger Lozano, Tooele High School
David Carter, Viewmont High School
Kevin Tomas, West High School
Rachel Holley, Westlake High School
Location: Main Library, Gallery at Library Square
Contact Information: (801) 524-8200


text:
click image to zoom
click to expand
Men's UA Chain Link Icon
Sorry, this item is
currently sold out.
Questions? Contact us:
what's it do?
UA graphic T's are like all our other T's—performance is built right into their DNA. This T-shirt is made from Charged Cotton® so it still has the familiar comfort of cotton, but dries much faster, so you'll stay cooler when you go to work.
The fundamentals
- Regular: A slimmer athletic cut that delivers better mobility by eliminating the bulk of extra fabric.
- Lightweight Charged Cotton® has the comfort of cotton, but dries much faster
- Signature Moisture Transport System wicks sweat away from the body
- Anti-Odor technology prevents the growth of odor causing microbes
- Durable ribbed collar provides a comfortable fit
- Cotton/Polyester
- Imported

subset: commoncrawl


text:
Gene Signatures Enhance Breast Cancer Risk Estimates
Combining gene signatures for breast cancer with clinical factors such as patient age and tumor size can improve predictions about the risk of recurrence in women with early-stage disease, new research suggests.
This strategy may also help physicians select the most appropriate chemotherapy regimens for women who undergo additional (adjuvant) therapy to prevent recurrences, the researchers report in the April 2 Journal of the American Medical Association.
Gene signatures are characteristic patterns of gene activity in cells that may reflect the underlying disease biology. A number of breast cancer signatures have been developed to predict clinical outcomes and several are being tested in trials such as TAILORx and MINDACT. Read more
Trial Suggests HRT Increases Breast Cancer Recurrence Risk
Long-term follow-up data from a randomized clinical trial indicate that, in women previously treated for breast cancer, use of hormone replacement therapy (HRT) significantly increases the risk of recurrence or contralateral breast cancer - a new cancer in the opposite breast. Published online March 25 by the Journal of the National Cancer Institute (JNCI), the analysis shows a 2.4-fold increased risk of recurrence or contralateral breast cancer in women randomized to receive HRT to treat menopausal symptoms compared with women given the best, nonhormonal treatments for such symptoms.
The trial, called HABITS, conducted in Scandinavia, was halted in 2003 after an interim analysis showed a 3.5-fold increased risk of cancer in women in the HRT arm. This longer-term analysis followed 442 women for a median of 4 years. Of the 221 women in the HRT arm, 39 had a "breast cancer event," compared with 17 of 221 in the control arm. Read more
Gene Signatures Enhance Breast Cancer Risk Estimates
Combining gene signatures for breast cancer with clinical factors such as patient age and tumor size can improve predictions about the risk of recurrence in women with early-stage disease, new research suggests.
This strategy may also help physicians select the most appropriate chemotherapy regimens for women who undergo additional (adjuvant) therapy to prevent recurrences, the researchers report in the April 2 Journal of the American Medical Association.
Gene signatures are characteristic patterns of gene activity in cells that may reflect the underlying disease biology. A number of breast cancer signatures have been developed to predict clinical outcomes and several are being tested in trials such as TAILORx and MINDACT.
Building on this work, researchers at the Duke Institute for Genome Sciences and Policy and their colleagues have now tested the hypothesis that biological information in breast cancer gene signatures is independent of clinical risk factors and that integrating these two sources of information can improve risk assessment beyond traditional methods.
"We can predict who might respond to chemotherapy, but more than that, we can predict which type of chemotherapy may benefit a particular person," says lead investigator Dr. Anil Potti of Duke. "This is truly, in my mind, the next step in personalized medicine."
His team retrospectively analyzed nearly a thousand breast tumor samples for which there was clinical and pathological information. Using this information, they assigned nearly 600 samples to three risk groups: low, intermediate, and high.
The researchers then used gene signatures to further stratify the probability of recurrence among each risk group. The signatures include well-characterized genes involved in cell communication and other molecular pathways that are deregulated in the disease. The result was "clusters" of patients with a range of clinical outcomes, and the clusters were confirmed in 391 additional samples.
The researchers plan to validate the strategy in several prospective trials. The current results reflect the limitations of a large, retrospective study, which included tumor samples from different studies and in some cases lacked complete clinical data.
For instance, the status of the HER2 gene, which can affect prognosis, was not always known. Another limitation was the small number of patients within certain clusters, which hindered statistical comparisons.
It is only through very large studies that the true genetic diversity of breast cancer will be revealed, notes Dr. Chiang-Ching Huang of Northwestern University, who coauthored an accompanying editorial.
"Cancer is heterogeneous, and you cannot see the subtypes or the differences in the risk of relapse and responses to therapy in small numbers of cancers," says Huang. "This study shows that if we pool our efforts we can get large enough samples to see if there are real signatures with prognostic power."
With so many experimental gene signatures for breast cancer, what the field needs now are studies to assess these classifiers in concert, says Dr. Lisa Anne Carey of the University of North Carolina Lineberger Comprehensive Cancer Center, who was not involved in the research.
Such studies may further document genetic alterations in breast cancer subtypes and eventually lead to clinical tools.
"This is intriguing work that begs to be taken further," says Dr. Carey.
—Edward R. Winstead
Trial Suggests HRT Increases Breast Cancer Recurrence Risk
Long-term follow-up data from a randomized clinical trial indicate that, in women previously treated for breast cancer, use of hormone replacement therapy (HRT) significantly increases the risk of recurrence or contralateral breast cancer - a new cancer in the opposite breast. Published online March 25 by the Journal of the National Cancer Institute (JNCI), the analysis shows a 2.4-fold increased risk of recurrence or contralateral breast cancer in women randomized to receive HRT to treat menopausal symptoms compared with women given the best, nonhormonal treatments for such symptoms.
The trial, called HABITS, conducted in Scandinavia, was halted in 2003 after an interim analysis showed a 3.5-fold increased risk of cancer in women in the HRT arm. This longer-term analysis followed 442 women for a median of 4 years. Of the 221 women in the HRT arm, 39 had a "breast cancer event," compared with 17 of 221 in the control arm.
The results "suggest that [HRT] not only induces and promotes breast cancer, but also may stimulate the growth of tumor microdeposits in breast cancer survivors," concluded the study's lead author, Dr. Lars Holmberg from the King's College London School of Medicine, and colleagues.
Several observational studies have found no increased recurrence risk among breast cancer survivors taking HRT. However, the authors argued, "The majority of these observational studies were not formal studies that could control sufficiently for bias and confounding."
In addition, a similar randomized trial launched in Sweden at about the same time as HABITS showed a decreased risk of breast cancer recurrence associated with HRT. The two trials had several design differences that could account for the discrepancies, the researchers noted, including the use among many HABITS participants of a more potent progestagen in their HRT regimen. (No single HRT type was prescribed for the trial.)
In a related commentary in JNCI, Dr. Kathleen Pritchard from Sunnybrook Odette Cancer Center in Toronto, Canada, indicated that the HABITS data are convincing.
"It seems that the harmful side effects of HRT [in breast cancer survivors] have finally been clearly demonstrated in what is, by today's standards, a small randomized trial, carried out in a few relatively small countries," Dr. Pritchard wrote.
Vaccine Treats Breast Tumors in Mice
A new therapeutic vaccine designed to stimulate the body's immune system so that it recognizes cancer as an invader shows promise in eradicating some advanced breast cancer tumors in mice. The study results appeared March 15 in Cancer Research.
The research team, led by Dr. Jay Berzofsky of the Vaccine Branch in NCI's Center for Cancer Research, engineered a vaccine using a modified adenovirus to code for portions of a protein called neu, which corresponds to human epidermal growth factor 2 (HER2) in humans - a surface receptor overexpressed in 20 to 25 percent of women who have breast cancer.
Mice were injected with mouse breast cancer cells called TUBO cells to generate tumors with high levels of neu. When the TUBO cells and vaccine were given at the same time, no tumors formed. When the vaccine was given after the TUBO cell injection, small tumors formed, but they disappeared within 45 days and did not reappear.
The larger the tumor load, the more difficult it was for a vaccine-induced immune response to cause these tumors to shrink and disappear. Tumors up to 2 cubic centimeters continued to grow for a week after immunization but disappeared within a month. Even tumors up to 3.5 cubic centimeters eventually disappeared. But tumors that were 5.5 cubic centimeters at the time of vaccination resumed growth after initial shrinkage.
The sooner the vaccine was given after TUBO cell injection, the lower the incidence of metastasis to the lungs, as well. With metastasis, it took longer for the immune response to clear the cancer if a large number of tumors were present. Mice with more than 200 metastases were tumor-free within 38 days.
"A vaccine offers several advantages over a monoclonal antibody treatment, which targets a single region on a receptor," said Dr. Berzofsky. "A vaccine may induce the production of several different antibodies and target multiple regions on a receptor, making it harder for the tumor to mutate and escape the effects of therapy."
Dr. Berzofsky added, "These results in mice show the potential for producing a vaccine that induces antibodies to an overexpressed cell surface receptor such as HER2 in breast cancer patients."
Guidelines for Colonoscopy Follow-up Assessed
The size and number of polyps removed during colonoscopy may be of limited use in predicting a recurrence that leads to cancer, new research suggests. The findings, in the March 18 Annals of Internal Medicine, raise questions about the current guidelines on follow-up colonoscopies, which define a schedule for surveillance exams based on detected polyps, or adenomas.
For patients with an advanced adenoma - considered high risk for becoming cancerous - or with at least three adenomas, the guidelines recommend follow-up within 3 years. For patients with fewer, nonadvanced polyps, repeat exams are recommended in 5 to 10 years. Surveys show, however, that many physicians schedule follow-up colonoscopies earlier than the guidelines suggest.
One reason may be that the guidelines have not been assessed in a prospective study. To explore this question, Dr. Adeyinka O. Laiyemo of NCI's Division of Cancer Prevention and his colleagues studied 1,905 patients in the Polyp Prevention Trial. Participants had an adenoma removed at baseline and underwent repeat colonoscopy at 1 year and 4 years.
In this study, the risk stratification model used in the current guidelines did not reliably predict the recurrence of advanced adenomas. Overall, 6.6 percent of participants had an advanced adenoma recurrence at 4 years. The advanced adenoma rates were 9 percent and 5 percent in patients with high-risk and low-risk adenomas at baseline colonoscopy, respectively.
An editorial accompanying the paper notes that while this difference is statistically significant, it may not be meaningful to patients and clinicians, given that the predictive accuracy of the current risk model is only 71 percent. (By contrast, the predictive accuracy of flipping a coin is 50 percent.)
Dr. Laiyemo stresses the need for more reliable tools to identify individuals at the highest risk for advanced adenoma recurrence. The misclassification of cases may mean that preventable colon cancers are missed or that limited medical resources are allocated poorly.
The researchers also found that patients are at high risk if they have two adenomas and one is on the right side of the colon, near the small intestine. The reason for this apparent association, which has been suggested in other studies, is not yet clear.
Oncogene Identified in Diffuse Large B-Cell Lymphoma
Researchers have identified how mutations in a gene called CARD11 contribute to cancer cell survival in a type of diffuse large B-cell lymphoma (DLBCL) with poor prognosis, called activated B-cell-like (ABC) DLBCL. The study results, published March 21 in Science, identify CARD11 as a possible future target for new therapies.
To prevent cell death, malignant ABC DLBCL cells rely on the nuclear factor-kappa B (NF-κB) signaling pathway - a cell-signaling pathway that plays an important role in cell proliferation, differentiation, and survival. NCI researchers previously reported that CARD11 stimulates abnormal cellular signaling of the NF-κB signaling pathway in ABC DLBCL. However, the underlying mechanism for this abnormal cellular signaling was not known.
To determine how CARD11 contributes to cancer, the researchers sequenced the gene in samples taken from ABC DLBCL biopsies and cell lines. They found that all of the CARD11 mutations coded for a region of the CARD11 protein called the coiled-coil domain.
As determined by fluorescence microscopy, mutant CARD11 proteins were more likely to aggregate (bunch together), and the degree of aggregation correlated with the protein's ability to activate the NF-κB pathway, thereby helping malignant cells survive. In a set of experiments using small hairpin RNAs to knock out mutant CARD11 function, cells from an ABC DLBCL line with mutant CARD11 died when the gene was blocked; these cells were not saved when researchers introduced a normal CARD11 gene, indicating an "addiction" to the mutant signaling pathway.
"Our results demonstrate that CARD11 is a bona fide cancer-causing gene in DLBCL, thus providing a genetic rationale for the development of drugs that could block the CARD11 pathway," concludes Dr. Louis Staudt from NCI's Center for Cancer Research, senior author of the study.
Expanding the Role of Advocates in Shaping, Enhancing Cancer Research
Everything we do at NCI begins and ends with the cancer patient in mind. In our ongoing quest to maintain that focus, NCI is fortunate to receive expert outside advice and recommendations from four federal advisory committees, each offering a unique perspective on how we can best serve patients.
The Director's Consumer Liaison Group (DCLG) brings to NCI the thoughts and concerns of those who have faced cancer, in their own lives and in the lives of those whom they represent. The DCLG is a forum for lay representatives to discuss NCI programs and, together with scientific experts, help develop a shared vision and understanding of today's best science and where tomorrow's research will take us. The ability of DCLG members to understand the science of cancer, the challenges of its complexities, and the opportunities to change the course of disease through investment in science provides NCI with a remarkable tool for communicating NCI's mission and accomplishments.
At the time the DCLG was conceived, NCI's ability to engage members of the cancer advocacy community was limited. Today, in large part because of this board, NCI routinely includes advocates and prepares them to participate in the review of grants, the planning of scientific programs, and the development of educational materials. Yet, there is more we could do together.
Last fall, the DCLG, at my request, convened a working group of advocacy leaders - with widely varying cancer experiences and backgrounds - to recommend how NCI can most effectively involve advocates in our work to help accelerate progress, benefit patients, and improve public health.
During last Thursday's DCLG meeting, the Advocates in Research Working Group discussed its progress on a report slated to come before the full DCLG in October. My thanks to the members of the working group, who are putting in many hours and carefully considering better ways we can work together, from the scientific education of cancer advocates to greater participation in and knowledge of clinical trials. The DCLG is uniquely positioned to facilitate communication across the advocacy community, and we have every hope that the working group's report will spark important discussions.
Last year, recognizing the importance of the advocacy community, NCI realigned the Office of Advocacy Relations (OAR), bringing it into the Office of the Director. Acting on a charge to enhance NCI's relationships with our external stakeholders, OAR is, today, closely considering how it forges connections between NCI and the advocacy community, at both the individual and organizational levels, and how we can do better. A cornerstone of these connections is the DCLG. We need the DCLG to be a strategic partner, informing NCI activities and coordinating support activities in the community.
To that end, we must utilize the DCLG as an important resource, for NCI and for the National Cancer Program. We have long talked about the need to focus on our common interests rather than accentuate our differences. It is a message that bears frequent repetition. Indeed, if we are going to make a difference in the course of these diseases, we must be united in purpose and speak with a common voice.
The DCLG, along with NCI's other advisory boards, will be a key player in disseminating this message of unity and working together across the diverse cancer community to enhance the efficacy of our vast cancer research enterprise and its ultimate goal of changing the face of cancer.
Dr. John E. Niederhuber
Lung Cancer Test Aims to Improve Early Detection
When an imaging test shows a suspicious mass in the lungs of a smoker, the next step is a bronchoscopy. A thin tube with a camera is passed into the person's airway to look for abnormalities and collect tissue for biopsy. But in many cases the results do not reveal whether the person has cancer.
At this point, a physician may decide, based on the available evidence, to pursue more invasive testing or to monitor a patient - a "watch and wait" approach. Unfortunately, there are no validated diagnostic tests or biological markers that reliably distinguish between smokers with and without the disease.
Researchers in Boston hope to change that. They have developed a genomic test that analyzes the activity of 80 genes in cells from a patient's airway. The airway cells, which can be collected during bronchoscopy, appear normal under the microscope, but they may have abnormal patterns of gene activity associated with lung cancer.
The test is based on the idea that toxins in cigarette smoke alter the behavior of genes throughout the respiratory tract - not just in the tumor - and that these changes have diagnostic value.
"The goal of this research was to identify gene expression patterns that can distinguish smokers with and without lung cancer," said Dr. Avrum Spira of Boston University School of Medicine, who co-led the project.
Preliminary results reported last year showed that the genomic test and bronchoscopy together were a better predictor of lung cancer than either test alone. There were even hints that the combination may improve the detection of small lesions or early-stage cancers - the ones more likely to respond to therapies and most often missed by bronchoscopy.
Dr. Spira discussed the test last month at the annual meeting of the NCI-sponsored Early Detection Research Network. A theme of the meeting was the need for biological markers with clinical relevance, as the lung cancer genomic test aims to be. EDRN and Dr. Spira are discussing ways to move this test towards clinical validation.
"This test addresses a serious dilemma in the clinic," said co-investigator Dr. Marc Lenburg of Boston University. "It's a real-world problem."
The need for better diagnostic tools is clear. Bronchoscopy detects stage 1 lung cancer in only 15 to 20 percent of cases, so physicians must move on to more invasive and more expensive tests, including exploratory surgeries, to determine if the lesions they see are cancer, according to Dr. Jerome Brody, who directs the Boston University Pulmonary Center and helped develop the genomic test.
As with all biomarker candidates, the 80-gene signature is experimental and must be validated in a large, well-designed study. A trial is being planned to evaluate the genomic test in 300 patients in the United States and Europe.
The validation study will also explore whether the genomic test can help physicians identify the subtype of lung cancer a person has and the underlying genetic flaws. This information could help physicians identify the most appropriate therapies for patients.
All three researchers have financial interests in a company called Allegro Diagnostics, which has raised funds to validate and extend this study and to make the test available commercially.
The researchers describe their approach as a "clinicogenomic" prediction model. In a study published online yesterday in Cancer Prevention Research, they say that the clinical and genomic information is both complementary and synergistic.
"What's new here is the combining of the genomic data with clinical information to develop a statistically valid predictor of lung cancer," said Dr. Brody, who was not an author of the most recent study. "This is one of only a few studies in any cancer that has attempted to combine the two in a statistically valid fashion."
The prediction model may expedite more invasive testing and appropriate therapies for smokers with lung cancer and reduce invasive diagnostic procedures for individuals without lung cancer, the authors conclude.
—Edward R. Winstead
Managing Bone Metastases: Can Radiopharmaceuticals Help?
When cancer spreads to bone during the advanced stages of disease, the results can be devastating. Some patients experience severe pain and face an increased risk of fractures and other skeletal-related complications. These often require additional treatments and may further diminish a patient's quality of life and compromise survival.
As systemic anticancer therapies improve, the problem of bone metastases is likely to become increasingly common, and new, cost-effective therapies are needed. Toward this end, a strategy aimed at preventing or delaying skeletal-related complications from bone metastases is being evaluated in a prospective, randomized NCI-sponsored clinical trial.
The researchers are testing whether a drug called zoledronic acid (Zometa), a standard therapy for patients with bone metastases, is more effective when given with a radiopharmaceutical such as strontium-89 or samarium-153. Radiopharmaceuticals are bone-seeking radioactive agents that incorporate into areas of bone being turned over by metastases.
The beauty of radioisotopes, which are administered intravenously, is that they target all bone metastases with a low concentration of radiation in the surrounding normal bone marrow and other structures, according to the researchers.
"If a patient has 30 to 40 spots on an affected bone, the radioisotope would go to all of the sites," said co-principal investigator Dr. Michael J. Seider of Summa Health System Hospitals in Akron, OH. "It is a fast, simple, and relatively non-toxic drug."
The trial, Dr. Seider noted, is asking a simple question: "If we add a radioisotope to a drug that already works in delaying skeletal-related events, will we further delay these skeletal-related events?"
The randomized, phase III study is enrolling patients with three cancers that commonly spread to bone - lung, breast, and prostate. To enroll in the study, participants must have bone metastases but no significant bone pain. All participants will receive zoledronic acid as a primary treatment and half will receive a single dose of a radioisotope. (The trial presumes that either radioisotope is acceptable for treatment.)
Participants will be followed for the development of pain and skeletal-related complications. During the trial, patients may receive any other type of therapy, including cytotoxic therapy, hormone therapy, or additional radiation therapy (except for treatment of bone metastases).
This point is critical because there is a misperception, particularly among some medical oncologists, that patients taking radioisotopes cannot receive other therapies at the same time. Studies have shown, however, that radioisotopes can be given with other therapies without causing more side effects than other combination therapies.
"We need to debunk the misconceptions and fears that exist regarding radiopharmaceuticals," said co-lead investigator Dr. Corey Langer of the Fox Chase Cancer Center. "The big problem with this class of drugs is the false impression that once you give them to patients their marrow function never recovers. We certainly are not seeing that in this trial."
To date, the trial has enrolled more than 50 of a planned 352 participants. It includes a component that will measure quality of life. Another question is the cost effectiveness of the combination therapy, because delaying the need for additional treatments for skeletal-related events could prevent expensive procedures.
If the trial is successful, noted Dr. Langer, the combination therapy could improve the lives of many patients with bone metastases by minimizing their pain and delaying further complications.
The current challenge is to overcome the notion that giving radioisotopes would prevent patients from getting any other type of therapy. "If we can break through this misconception, the study looks to be very promising," said Dr. Seider.
—Edward R. Winstead
Following are newly released NCI research funding opportunities:
Functional Links between the Immune System, Brain Function, and Behavior
Application Receipt Dates: Non-AIDS Applications (new): June 5, Oct. 5, 2008; Feb. 5, June 5, and Oct. 5, 2009; Feb. 5, June 5, and Oct. 5, 2010; Feb. 5, 2011
This is a renewal of PA-07-088 and will use the R01 award mechanism. For more information, see http://researchportfolio.cancer.gov/initiativedetail.jsp?InitiativeID=3860. Inquiries: Dr. Paige McDonald - firstname.lastname@example.com.
Multicenter AIDS Cohort Study (MACS), Limited Competition
Application Receipt Date: June 10, 2008
This is a reissue of a limited competition to continue the longitudinal MACS and will use the U01 award mechanism. For more information see http://researchportfolio.cancer.gov/initiativedetail.jsp?InitiativeID=3864. Inquiries: Dr. Rebecca Liddell Huppi - email@example.com.
Tumor Stem Cells in Cancer Biology, Prevention, and Therapy
Letter of Intent Receipt Date: June 10, 2008
This funding opportunity will use the P01 award mechanism. For more information see http://researchportfolio.cancer.gov/initiativedetail.jsp?InitiativeID=3857. Inquiries: Dr. R. Allan Mufson - firstname.lastname@example.com.
Functional Links between the Immune System, Brain Function, and Behavior
Application Receipt Dates: Non-AIDS Applications (new): June 16, Oct. 16, 2008; Feb. 16, June 16, and Oct. 16, 2009; Feb. 16, June 16, and Oct. 16, 2010; Feb. 16, 2011
This is a renewal of PA-06-533 and will use the R21 award mechanism. For more information, see http://researchportfolio.cancer.gov/initiativedetail.jsp?InitiativeID=3860. Inquiries: Dr. Paige McDonald - firstname.lastname@example.com.
Optimizing Technologies for the Preservation of Fertility
Letter of Intent Receipt Date: Aug. 15, 2008
This funding opportunity will use the R21 award mechanism. For more information see http://researchportfolio.cancer.gov/initiativedetail.jsp?InitiativeID=3862. Inquiries: Dr. Diana D. Jeffery - firstname.lastname@example.com.
Flat and Depressed Colorectal Growths May Change Screening
Unlike most cancers, colorectal cancer is considered preventable in many cases: prevailing opinion states that many malignancies found in the colon or rectum began years earlier as adenomas - noncancerous tumors that form in the linings, or mucosa, of these organs. Early detection and removal of these adenomas is the basis of screening for colorectal neoplasms.
Traditionally, doctors have focused on finding and removing polypoid adenomas - growths that protrude from the mucosa - during screening colonoscopy. But newer evidence suggests that flat (having a height less than half of the diameter) or depressed adenomas may be even more likely to harbor precancer or cancer, and may be more common than previously realized.
In a recent study published in the Journal of the American Medical Association (JAMA), investigators examined 1,819 patients undergoing colonoscopy for screening, surveillance, or symptoms of colorectal neoplasms. Although just over 9 percent of adenomas found were flat or depressed (known as nonpolypoid), these growths accounted for about 15 percent of identified neoplasms and 54 percent of high-grade dysplasia and submucosal invasive carcinoma in this series of patients.
Advanced cancers that arise from nonpolypoid adenomas are indistinguishable from those that arise from polyps. "If we had not intervened, if we had missed [the nonpolypoid adenomas], some of them would have become invasive cancers, and by that time we wouldn't know where they had come from, because they would have gone through the transformation to become bulky and invasive," says Dr. Roy Soetikno from the Veterans Affairs Palo Alto Health Care System and Stanford University, lead author of the JAMA study.
The overall prevalence of nonpolypoid colorectal neoplasms (NP-CRN) in the general population remains unclear, and scientists do not know if these types of adenomas grow or recur faster than the more common polypoid lesions. In an editorial accompanying the paper in JAMA, Dr. David Lieberman from Oregon Health and Science University writes that polypoid and nonpolypoid neoplasms missed during screening "may represent the most common explanation for interval cancers," that is, cancers that arise in between scheduled colonoscopies or other screening tests.
However, explains Dr. Barry Kramer, associate director for disease prevention at the National Institutes of Health, "we really don't know, because we really can't be confident about the natural history of these lesions. All we have at this point are cross-sectional studies; that is, what appears in the colon at the time of colonoscopy or sigmoidoscopy. If we're aware of polyps or flat adenomas [during screening], we take them out. And so we lose our ability to learn, at least with precision, what the natural history is.
"That's a gap in our knowledge at this point," he continues. "It will also be useful to know if there are differences in the molecular fingerprints between these lesions and the usual [polypoid] adenomas. If there are, that might help us predict the behavior of a given lesion, and that's an important area for research."
Two traits of NP-CRN agreed on by investigators are that they are more difficult to detect and more difficult to remove. Unlike polyps, which can be cut away from the intestinal wall fairly easily, removing NP-CRN involves a multi-step procedure called mucosal resection.
By training with Japanese endoscopists and studying videos of NP-CRN cases, Dr. Soetikno's team learned to look for the characteristic features of NP-CRN, which include a slightly red appearance, altered or absent vascular network, friability, and wall deformity. He believes that any interested physician can learn to recognize the lesions. "You need to have an imprinting of the shapes, of the color, in your mind…if people are willing to spend the time and look at [training] movies and really imprint them in their minds, I think people can learn."
His research group plans to make their training materials available to interested endoscopists through the American Society for Gastrointestinal Endoscopy. "The technique of mucosal resection also needs to be disseminated, so the benefit of finding these flat lesions can be maintained," he adds.
Another screening test called virtual colonoscopy - also known as CT colonography - which uses computed tomography (CT) to visualize the GI tract noninvasively, has been tested recently in clinical trials.
While researchers are debating how to optimize CT colonography to better detect truly flat or depressed lesions, Dr. Perry Pickhardt, associate professor of radiology at the University of Wisconsin Medical School, believes that most "lesions the JAMA paper describes are things that we see routinely, and with current techniques we really don't have much problem finding those lesions. I think awareness is the main thing, and that's a very important message: be aware of these."
"We're still developing techniques to optimize both colonoscopy and CT colonography…as there's increasing awareness that [nonpolypoid lesions] exist and are relatively common," says Dr. Kramer.
"The future of screening for colorectal neoplasms is to detect and remove all neoplastic lesions: polypoid and nonpolypoid. By having data to show the existence and importance of the flat and depressed lesions in the United States, we can alert all endoscopists," said Dr. Soetikno. "Our patients, referring physicians, and insurers expect that when we give a patient a clean bill of health, we do not leave any neoplasms behind."
—Sharon Reynolds
Batracylin for Patients with Advanced Solid Tumors or Lymphoma
Name of the Trial
Principal Investigator
Why This Trial Is Important
Along with the development of such targeted therapies, researchers have explored the possibility of matching the genetic characteristics of patients to treatments that may be especially suited to them. The drug batracylin is an example of a targeted therapy that may prove beneficial to patients with certain genetic characteristics.
Batracylin inhibits two proteins, topoisomerase I and topoisomerase II, that are overabundant in certain types of cancer cells and may play a role in cancer formation and progression. Drugs have been developed that target one or the other of these proteins, but batracylin is the first drug to reach human clinical trials that targets them both.
Although this ability makes batracylin a promising anticancer agent, early testing in animals indicated that different species process the drug differently, with some species processing it very quickly, resulting in unacceptably severe side effects. Subsequent research showed that a cellular process called acetylation occurs more rapidly in these species, causing them to process batracylin more quickly. This finding led researchers to theorize that humans whose genetic characteristics cause slow acetylation would be able to tolerate and benefit from treatment with batracylin.
In this trial, patients with solid tumors or lymphomas for which standard therapies do not exist or are of minimum benefit and who are slow acetylators, as determined by a blood test, will be treated with increasing doses of batracylin. Researchers hope to assess the pharmacokinetics of batracylin in these patients and determine the most appropriate dose for future clinical trials.
For More Information
An archive of "Featured Clinical Trial" columns is available at http://www.cancer.gov/clinicaltrials/ft-all-featured-trials.
The next "Understanding NCI" teleconference will take place on April 10 from 2:00 to 3:00 p.m., EDT. The topic is "Clinical Trials in Your Community: NCI's Community Clinical Oncology Program (CCOPs)." The call will feature Dr. Lori Minasian, chief of NCI's Community Oncology and Preventive Trials Research Group; Dr. John Kugler, a principal investigator with the Illinois Oncology Research Association CCOP; and Ms. Laura Matus, volunteer coordinator of Illinois CancerCare.
Within the U.S., the teleconference can be accessed toll-free at 800-857-6584; the passcode is: Prevention. Toll-free playback will be available through May 10 at 800-284-7027.
To learn about the "Understanding NCI Teleconference Series" and to learn about past teleconferences, please visit: http://advocacy.cancer.gov/.
DCLG Seeks New Members for 2008
The DCLG is a federally chartered advisory committee of the NCI. It consists of 16 consumer advocates who are involved in cancer advocacy and who reflect the diversity among those whose lives are affected by cancer. The mission of the DCLG is to advise, assist, consult with, and make recommendations to the NCI Director, from the perspective and viewpoint of cancer consumer advocates on a wide variety of issues, programs, and research priorities. The DCLG serves as a channel for consumer advocates to voice their views and concerns.
Please visit the DCLG Web site at http://dclg.cancer.gov/membership/nominations for information on the application process and to view eligibility requirements.
Free Telephone Workshop Series for Cancer Survivors
The program is a collaborative effort between NCI, CancerCare, the Lance Armstrong Foundation, the Intercultural Cancer Council, Living Beyond Breast Cancer, and the National Coalition for Cancer Survivorship.
The workshops are free; no telephone charges apply. To register, visit the CancerCare Web site at www.cancercare.org/TEW. All workshops will take place on Tuesdays from 1:30 p.m. to 2:30 p.m. EDT on the following dates:
Part I: "The Importance of Communicating with Your Doctor about Follow-Up Care," April 22
Part II: "Rediscovering Intimacy in Your Relationships Following Treatment," May 13
Part III: "Survivors Too: Family, Friends, and Loved Ones," June 24
DCLG Remembers Kerry Dewey
After her diagnosis, Ms. Dewey became a patient advocate. She was a trainer with the American Cancer Society Reach to Recovery program and she initiated and led several support groups, including a peer support group for spouses, partners, and male family members called "Male Call." Due to her advocacy work and efforts to develop a statewide resource for patients and families called The Montana Breast Cancer Resource Guide, she was selected as a member of the DCLG in 1997 and served until 2001.
Mr. Mike Katz, a former DCLG chairperson, said of Ms. Dewey: "Kerry was one of our committee's most impactful members. She was wonderfully soft spoken, with a lovely sense of humor. She sometimes single-handedly brought our most outspoken advocates from the big metro areas back to earth about the unique challenges faced by cancer patients in rural areas. There isn't anyone who met her who didn't come away with a special affection for a person who was clearly one of Missoula's finest and one of its most effective ambassadors."
NCI Issues Colorectal Cancer Progress Report
National Smoking Cessation Campaign Launched
The program consists of paid TV, radio, and internet ads; a Web site (www.BecomeAnEx.org); and a free quit plan book. The EX program also includes a research component. The EX Smoking Cessation Panel Study will collect survey data via telephone interviews with adult smokers over a 2-year period.
NCI is participating in this effort by providing funding to assist with the evaluation of EX, which was launched by an alliance of the nation's leading public health organizations and 14 states called the National Alliance for Tobacco Cessation (NATC). Members of the NATC include the American Cancer Society, the American Heart Association, the American Legacy Foundation, the Robert Wood Johnson Foundation, the Association of State and Territorial Health Officials (ASTHO), the Mayo Clinic, and others.
U.S. Military Health Program Provides Coverage for NCI Clinical Trials
Effective today, the U.S. Department of Defense's (DoD) TRICARE health care program and NCI have renewed their interagency agreement to provide TRICARE beneficiaries with more options for cancer care and greater access to advances in cancer prevention and treatment through clinical trials. The decision is based on a successful 10-year DoD-NCI demonstration project in which more than 800 members of the armed forces and their families have participated in NCI trials.
NCI Director Dr. John Niederhuber concurred: "One of NCI's highest priorities is to ensure that our latest science - new treatments and new prevention methods - is available to all patients in the communities where they live. Our agreement with TRICARE helps advance that goal." He also expressed hope that TRICARE's actions will serve as a model for other health insurers to add or expand their beneficiaries' coverage of NCI- and other NIH-sponsored clinical studies.
TRICARE's benefit allows the program's 9.2 million beneficiaries to take part in phase II and phase III NCI-sponsored cancer clinical trials, including studies for prevention, screening, early detection, and treatment. All medical care for trial participants will be provided by Military Treatment Facilities (MTFs) or civilian providers participating in NCI-sponsored studies. In a press release, TRICARE noted that there are more than 2,000 sites - including MTFs, civilian providers, and comprehensive cancer centers - that offer cancer trials.
The agreement also allows all DoD MTFs and authorized TRICARE providers involved in oncology care to apply for participation in NCI clinical trial protocols for adult and pediatric cancers according to the usual NCI participation review process.
"Through this agreement, all TRICARE beneficiaries will have access to some of the most promising advances in cancer research through NCI-sponsored clinical trials throughout the country," added U.S. Army Major General Elder Granger, deputy director of the TRICARE Management Activity.
Retired Army Sergeant Major Michael Adams participated in the DoD-NCI demonstration project after he was diagnosed with advanced prostate cancer two years ago at age 47. "I had no knowledge of clinical trials before I was diagnosed and started searching the Internet," he explained. "When I searched the term 'clinical trials,' that ultimately led me to the TRICARE Web site which described the DoD-NCI demonstration project."
Sergeant Adams was referred to Memorial Sloan-Kettering Cancer Center where he entered a trial examining alternative methods of surgical anesthesia. "This program saved my life," he said. "When I first started in the program and came in to see the surgeon at Sloan-Kettering, he realized the severity of my diagnosis and literally cleared his schedule to make me his next patient."
He recalled: "I've never experienced such care in life, and I'm a combat vet who has had multiple surgeries in the past. I was treated at one of the world's leading cancer treatment centers. They are very supportive to patients and their families. They even spent time with my wife to explain my treatment and recovery, which is a very important part of my care."
Sergeant Adams is very pleased about TRICARE's decision to continue partnering with NCI. "I would highly recommend the program and clinical trial participation to other military personnel and their families," he said.


text:
The Next Generation 30 Drugs Discovery Summit brings together 30 senior decision makers and business leaders from across the region.
No Previous Summits Available
The NG30 Drug Discovery Europe brings together 30 senior decision makers and business leaders from across the region.
The event aims to solve your key business challenges. In particular, the ability to network and learn from industry peers through essential business conversation shaped by our three unique drivers of opportunity:
We conduct comprehensive, first-class research
We invite only the most senior representatives from the region's largest organisations
We provide an environment conducive to high-level networking and collaboration
This NG30 Drug Discovery Europe is invitation-only, if you would like to find out more about the program or attendees, please contact Oliver Smart.
Oliver Smart
Chief Executive Officer
E: firstname.lastname@example.com
When I was asked to participate in this event as a delegate, I was quite sceptical about the value of this event to me, my group and my company. However, this view has completely changed – the networking opportunities were excellent"
George Okafu, GSK


text:
Tech Air 17.3 inch Laptop Case and Mouse
- In Stock
30 reviews
- Delivery
This stylish, lightweight TechAir laptop case is suitable for 17.3 inch laptops and comes with a silver optical mouse included.
Foam padded inner protection and a securing strap keep your laptop safe from bangs, knocks and scratches wherever you get to. It's also showerproof for when you get caught out in the rain.
You can carry your laptop case either by the padded handle or by using the detachable, adjustable shoulder strap.
Useful info:
- TechAir Z0105 17.3 inch classic laptop case
- Silver 800dpi optical mouse included
- Front pocket for your power leads and accessories
- Detachable, adjustable shoulder strap
Tech Air 15.6 inch Laptop Case and Optical Mouse
- In Stock
36 reviews
- Delivery
Techair Z0105 15.6 inch classic case and silver 800dpi optical mouse. Case suitable for 15.6 inch laptops. Front pocket for your power leads and accessories. Adjustable strap. Detachable shoulder strap. 1 other pocket.Colour: Black.


text:
PhD, London School of Economics
Dr. Wagemans is Director at PricewaterhouseCoopers, leading the Public Services Advisory Practice. Prior to PwC, he was a strategy consultant at Arthur D. Little. He holds a Ph.D. in Political Economy from the London School of Economics. He was the recipient of the Hoover Foundation Fellowship while at Brown University and has been Visiting Fellow at Oslo University.


text:
Kids Paintball Party
- 200 rounds of paintball ammo each
- Half days play
- Multiple Missions
- Semi Automatic Machine Gun
- Freshly laundered combat overalls
- Experienced and Uniformed Marshalls
Go Ballistic paintball the best way for children to experience paintball.
Young Guns with Go Ballistic includes the following for only £19.50 per player
The minimum age for paintball in the UK is 12 years old.
The absolute minimum age for paintball in the UK is twelve years old. It is illegal and irresponsible to allow any child who has not seen his or her twelfth birthday to play paintball. Go Ballistic® as a responsible supplier of paintball games does not accept players under twelve years old.
All children under the age of 16 must bring a completed parental consent form on their game date. Download the Form Here
Why choose Go Ballistic® paintball for your children?
- Officially the UK's most popular choice for Childrens Paintball
- Europes busiest paintball sites
- Child Friendly Marshalling
- Amazing Game Zones
- Fully inclusive Young Guns Package
- Easily Accessible
- UKPSF registered
How to book your Childrens session at Go Ballistic® Paintball.
You need to pay the full £19.50 game fee per person to secure the booking. Go Ballistic paintball sites are incredibly busy so try to book at least two weeks in advance.
*some sites have a higher minimum age than twelve years old - always check before booking. Young Guns package is available at participating sites only.
Birthday Party Invitations
Planning a Birthday Party? If you are, take a look at our FREE birthday party invitations and posters.
- Invitation - Download Now!
- Poster - Download Now!
Please Note: All children under the age of 16 must bring a completed parental consent form on their game date. Download the Form Here
Select an Event
Select a Location
We have 120 Paintball Site's in the UK and Ireland. Use the map above to find a Paintball Site in your area or click here to view all our Sites


text:
- 1 Student arrested after lying to instructor, official says
- 2 UA football: Pair of defensive players leave team
- 3 UA student assaulted in parking garage
- 4 A-10 removed from runway at D-M
- 5 Calif.-based fast-pizza restaurant opening in Tucson
- 6 UA football: Wright's goal: 'Go get the ball'
- 7 Feds: Arizona lacks authority to ban licenses for Dreamers
- 8 Arizona Wildcats will face unusually colored Ducks Thursday
- 9 Can a Wildcat be Pac-12 POY?
- 10 Pieology opening first Tucson restaurant Wednesday
NBA notebook: Anthony top scorer; Curry breaks record - Comments
We welcome your comments. Commentary and photos submitted to StarNet (azstarnet.com) may be published or distributed in print, electronically or other forms. Opinions expressed in azstarnet.com's comments reflect the opinions of the author, and are not necessarily the opinions of the Star, StarNet, or its parent company. See the Terms of Service and Privacy Policy for more information.
Our guidelines prohibit the solicitation of products or services, the impersonation of another site user, threatening or harassing postings and the use of vulgar, abusive, obscene or sexually oriented language, defamatory or illegal material. You may not post content that degrades others on the basis of gender, race, class, ethnicity, national origin, religion, sexual orientation, disability or other classification. It's fine to criticize ideas, but ad hominem attacks on other site users are prohibited. Users who violate those standards may lose their privileges on azstarnet.com.
You may not post copyrighted material from another publication. (Link to it instead, using a headline or very brief excerpt.)
No short set of guidelines such as this can spell out all possible instances of material or behavior that we might deem to be a violation of our publishing standards, and we reserve the right to remove any material posted to the site.
Most Popular
Follow the Arizona Daily Star
Featured businessesView more...
Deals, offers & eventsView more...
$15.99 Oil Change Special!
K&D Quality Auto is offering $15.99 conventional 10w30 oi…
Arizona Cactus Ranch has been proudly serving the Tucson area for many years and takes pride in producing the best prickly pear products available.
We offer 100% pure, concentrated Prickly Pear Nectar. The nect…
Do you have unwanted Dog or Cat orders? Let Sunshine Carpet Cleaning of Tucson bring back the sunshine in your home with our 10 step carpet cleaning process. cal us at 520-319-0196
Sunshine Carpet Cleaning uses the most innovative equipment an…
Planning an Anniversary Party? Check Out Angelica's Wedding & Event Center
Angelica's is a calm, beautiful oasis where your friends and f…
Sweet P's Luxury Organic Skin Care is having a Sun Protection Sale for June. Enjoy 30% off tinted lip glaze. Regular $15 on sale for only $10! (520) 909-1192
We have 11 different colors to choose from!


text:
Replacement sunhood, complete with sunhood frame, for your explorer or hammerhead stroller.
Once this limited stock is gone, we will no longer be manufacturing further explorer/ hammerhead fabric parts in any colour other than back/charcoal. Unfortunately if we are out of stock of what you are after in your region, the part is no longer available :(
This sunhood can also be used on the e3, classic, sport or dash buggies, although these models will not have sunhood locators for optimal placement.
*current navigator sunhoods can be retrofitted to your stroller
Want to receive updates about new products and promotions?
© 2014 philandteds.com


text:
Welcome to Loews Ventana Canyon
Experience the Very Best at Loews Hotels
Tucson's spectacular 'Ventana' or 'Window' to the Soul of the Sonoran desert—is Loews Ventana Canyon. Discover a magical perspective high above Tucson's Catalina Mountains, where this stunning natural retreat offers a variety of activities, signature services and experiences to relax, energize and inspire guests.
A playground of visitor delights includes: the luxurious Lakeside Spa & Tennis Center; Canyon hiking; professional stargazing; 2 Tom Fazio-designed PGA golf courses and lighted tennis courts; 2 swimming pools; a fitness center; nearby riding trails and more.
Relax in the comfortable elegance of one of our 398 spacious guest rooms, including 26 suites. Each features a private viewing balcony, oversized tub, and breathtaking views of the desert mountains and night sky.
Savor innovative twists on classic Southwestern cuisine—created by Chef Cathey—at The Flying V Bar & Grill. Enjoy our famous tableside guacamole and a Signature Cocktail while overlooking the 18th hole and serene desert terrain.
With more than 37,000 square feet of creative indoor function space--including our 10,800 square foot Kiva Ballroom—and nearly 40,000 square feet of spectacular outdoor space, it's no wonder that Loews Ventana Canyon is consistently awarded the prestigious Meeting & Conventions Gold Key Award.
For a complete list of hotel features and highlights, click here.


text:
Área de reservas
Establishments found
Elba Costa Ballena****
Avda Carla de Orleans s/n Urb. Costa Ballena. Rota, Cadiz
11520 COSTA BALLENA, ROTA (CÁDIZ), España
Tel: Work pref 956 84 92 00 Fax: 956 84 70 41
Built in the Mediterranean architectural style, the hotel is designed to house activities all year round, even in winter, as for example in the complete Thalasso-Spa.
A delightful stroll through the gardens leads one directly to the beach, the golf course, the paddle tennis court, the children's area with a wide variety of games and swings, or the pools.
Gran Hotel Elba Estepona & Thalasso Spa*****GL
Ctra. Estepona-Cádiz, 151
29680 ESTEPONA (MÁLAGA), España
Tel: Work pref 952 809 200 Fax: 952 809 201
E-mail: firstname.lastname@example.com
Everything in the hotel, from the unique architecture of its façade to its spectacular reception area opening wide on to the sea, the Mediterranean sky flooding it with light through its enormous glass dome, including its thalasso spa - a blend of classicism and modernity - and 4 restaurants offering a variety of styles and cuisines, with terraces giving on to the sea, absolutely everything combines in an exercise in style that invites our guest to savour the delights of hedonism.
Gran Hotel Elba Motril****
Avenida Playa Poniente, s/n
18600 MOTRIL (GRANADA), España
Tel: Work pref 958 607 744 Fax: 958 607 776
E-mail: email@example.com
A hotel to enjoy the year round:sun, snow, sea . all close at hand. With all the necessary facilities to guarantee an unforgettable holiday, and, thanks to its convenient position, to work in comfort.
Hotel Elba Almería****
Prolongación Avd. del Mediterráneo s/n
04009 ALMERÍA (ALMERÍA), España
Tel: Work pref 950 145390 Fax: 950 149 351
E-mail: firstname.lastname@example.com
A hotel that has all the services and technology you need for your work and business meetings.
100 comfortable and spacious rooms, thanks to our own standards of quality, that ensure that your stay with us will be a pleasant one indeed.
Organise your next function at ELBA ALMERIA function rooms and support services for conferences, seminars, company meetings, etc., catering in Almería for up to 300 people.
Hotel Elba Carlota****
Urbanización Fuerteventura Golf Resort, Carretera de Jandia Km.11
35610 FUERTEVENTURA (LAS PALMAS), España
Tel: Work pref 928 160 326 Fax: 928 163 750
The Hotel is facing to the first 18-hole golf course on the Island of Fuerteventura and with excellent views to the Atlantic Ocean.
Just next to the hotel there is a Congress Centre, fully equipped with the latest technologies and with a capacity of up to 730 people.
Hoteles Elba
Table obtaining of Avios
|Category Hotel
|Hotels 5 *
|Hotels 4 *
|Hotels 3 *
Hoteles Elba
Table use of Avios
|Category Hotel
|Avios per night
|Hotels 5 *
|Hotels 4 *
|Hotels 3 *


text:
Picture by: AllrecipesVideo
Gazpacho soup is usually a summertime favorite. However, I find it enjoyable for dinner; it's light and satisfying. You and your family will enjoy it, too!
Make sure you have the following ingredients on hand, or add what you need to your shopping list.
1kg tomatoes, peeled and halved
1 clove garlic
1/2 onion, sliced
1 green capsicum, sliced
1 cucumber, peeled and sliced
Salt to taste
50ml extra virgin olive oil
25ml red wine vinegar
Cold water, as needed
To garnish
1/2 onion, chopped
1 green capsicum, chopped
1 cucumber, chopped
This Gazpacho recipe will serve 8.
Enjoy your delicious Gazpacho soup!
You will find other delicious recipes @ http://929wlmi.com/latest-updates/authors/34/


text:
To do the cool things, you have to be logged in first.
I'm a fan of haviing a r.o.y. point guard the bay area beast
This photo: Aldridge Posts Up Vs Memphis /
put this photo on your page
© 2004-2011 by the Portland Trail Blazers. All Rights Reserved.
Feedback / Privacy / Terms of Service / Trail Blazers Privacy / Trail Blazers Terms


text:
Just an update/announcement :)
Isaac's delivery (c/s) went very well - no nasty complications and everything went amazingly well. I'm amazed at how different it is when things go well - he came out ready to go and was crying before the cord was cut. What an experience, heh.
Anyway - he is a healthy 8lb 1oz, Mom is doing great (won't let me post her weight [:D] )


text:
- olapic-scroller
Wooden Wall Tree
- Overview
- Think outside the evergreen. This rustic Wooden Wall Tree is a fresh way to display gilded pinecones, silvery snowflakes and other light-catching ornaments—plus it takes up no floor space at all.
- Natural wood.
- 11"w x 35"h.
- Wipe clean.
- Imported.
- Details + Dimensions
Overall product dimensions: 11"w x 35"h.
Wipe clean.
- Shipping + Return Info
Most purchases are shipped from our Distribution Center by UPS, to arrive in your home within 5 business days of order receipt.
Shipping Rates
The shipping rate varies depending on your order total and shipping options. View Shipping Rates and Options
Rush Delivery
For an extra charge of $15 per address, we can arrange for rush delivery to most destinations.
Return Policy
We take great pride in the quality of our merchandise. If for any reason you are not happy with your purchase, you may return the item(s) within 30 days of receiving the order for a full refund of the merchandise cost. After 30 days, we will replace or refund your purchase against manufacturer's defects ONLY. Please note that we cannot accept returns on monogrammed/personalized items, special order upholstery items and special order rugs, one-of-a-kind rugs, or on items damaged through normal wear and tear. We also cannot accept returns of final-sale items, which are identified by a price ending in .99 or .97. Price adjustments will be honored within 14 days of purchase with original purchase receipt. Delivery fees are non-refundable. Returns of mattresses are subject to a $200 return shipping fee.
For further assistance please call our customer service department at 1.888.922.4119 or send an email to firstname.lastname@example.com


text:
Elomi Smoothing Strapless Bra
- Low stock, selling fast
30 reviews
- Delivery
Elomi Smoothing Strapless Bra
The Elomi strapless DD+ bra is a functional solution bra that offers the versatility of detachable fabric straps. This strapless plus sized bra is perfect for wearing with the summers favourite maxi dresses and bandeau tops.
This lingerie piece features ultra supportive foam moulded cups for great uplift and shape. It also features gripper elastic for increased support and anchorage. This means a great fit without compromising style or comfort.
Wear the Elomi strapless bra with a printed floral maxi dress or a soft strapless jersey top.
Useful info:
- Strapless bra by Elomi
- Smooth fabric and fit
- DD+ bra; foam cups
- Moulded cups for uplift
- Gripper elastic for anchorage
Panache Tango 11 Balconette Bra - Black, Nude, White
- Low stock, selling fast
67 reviews
- Delivery
Panache Tango ll Balconette Bra
This Tango ll balconette bra is a best selling Panache bra from the brand that's been flattering shapely figures for ten years now! With an underwired design this bra promises excellent support and a stunning shape.
The underwired balconette style of this piece gives a gorgeous shape under clothes. The Austrian embroidery is stylish and you'll love the colour update for the season ahead. It features three section cups for increased support and shape. The bow trim at the centre front is a feminine finish.
Wear this balconette bra by Panache under a scoop neck T-shirt or a fitted dress.
Useful info:
- Tango II balconette bra by Panache
- Fully laminated for a supportive fit
- Underwired design for shape and support
- Embroidered leaf design to cups
- Three section cups for increased support
- Bow trim finish to the centre front
- Soft plush on the front of the split straps on sizes GG plus


text:
His cute Asian babe just loves getting laid. She has some big tits that her partners just enjoy feeling and fucking between them when the chance arises. She gets cock any way that she can, in her mouth, from behind, riding like a cowboy until she has a pussy that she spreads so you can see she is dripping cum from her efforts. She is just the thing for a gift for that favorite guy in life; you know the one who has everything? Come check her yourself, she is hot and exciting and waiting to show it all off for you.
|Screenshots (Total 131)
|Comments (0)
|Detailed Info
|More Stuff
Yuria Satomi
Yuria Satomi is a hot Asian MILF in her office suit. She is in the break room with a co worker and he is interested in her sexy pantyhose and her pussy. She is making out with him and doing some hand work on his cock when he gets to her w..
Yuria Satomi
Round tit and horny babe Yuria Satomi making out and hardcore fucked. She tease and makes out with her hung lover and strips down on her sexy dress. She get her boobies squuezed and wet pussy licked. She humps on his cock, grinds on it ti..
More Yui Natsuki
Lustful Japanese AV model Ai Uehara takes a bath wearing adorable white swimsuit, and looks perfect in this wet lingerie. Her body looks juicy and arousing. He boyfriend soaps her playfully and fingers her lovely trimmed pussy, then she stuffs her mouth with dick and gets mouthful of cum.
Kinky Japanese schoolgirl Ai Uehara likes to deep suck huge cock before letting it slide down her precious vag and fuck her in hardcore school session. Amazing hottie loves to get nasty and moans hard when having it inside her holes. Naughty babe enjoys a rough drilling!
Arousing Japanese teen Ai Uehara enjoys deep sucking a hard cock in amazing and naughty oral session which makes her moan and have amazing pleasure feeling it sliding gently down her soft lips and inside her sexy mouth. She is a horny gal enjoying an equally horny guy!
Ai Uehara is a nice Asian teen in her white stockings and sexy dress. She is getting pussy stimulation with sex toys and a vibrator before she inserts her guy´s cock into her mouth for a blow job! She gets some hardcore action in a doggy style fucking and a load of cum on her sexy body!
Ai Uehara is a hot Asian babe who is enjoying getting a hard cock in her mouth for a hot blowjob! She is experienced in cock and her guy appreciates it as he is licking her wet cunt. She is sliding her mouth up and down his shaft until she gets a load of cum on her pretty face!
Lustful Japanese AV teen model Ai Uehara needs sex badly. This cute girl enjoys boobs pinching and pussy licking action. Her lover teases her pussy lips and massages her clit, and the girl licks his hot body before making a very hot and arousing cock riding session, and her boyfriend cums on her wet pussy.
Arousing Japanese teen Ai Uehara loves having her tight pussy finger fucked before penetrated deep by this hunk who loves hearing her moan during naughty hardcore action. Kinky teen loves having her hairy cunt filled with warm cream as she orgasms and moans.
Lustful Japanese AV girl Ai Uehara takes a bath together with her boyfriend. The sexy brunette pleases her lover, stimulating his sexy body. She licks his feet on amazing POV, and plays with his hard cock, making titty fucking and performing a playful blowjob action!
Young Japanese schoolgirl Ai Uehara is a real cock lover. She swanks in a miniskirt in front of her classmate and takes out his boner to make a tough tug job. She gets her big juicy boobs bruised and fondled, and enjoys hardcore pussy drilling by a sex toy, followed by rough doggystyle pounding.
You Might Also Like
Minami Aoi gets fucked by her tra..
Unsatisfied redhead Yui Ooba has ..
Tsubasa Amami ties up guy and giv..
Stunning Japanese milf Eri Hosaka..
Eccentric Japanese babe Nanami Sa..
Alluring Asian cutie Nanmi Kawaka..
Jessiaka Kizaki loves having her ..
Honami Uehara busty Asian milf sh..
Hairy pussy hole of naughty teen ..
Long-haired Japanese AV model giv..
Sexy Rin Sakuragi Asian milf amaz..
Lovely sex amateur Jessica Kizaki..
Related DVDs
- Relax Vol. 14: Dre..
- 83%61 min. 0 sec.
- My Teacher is a Ka..
- 76%111 min. 21 sec.
- Liberation
- 65%104 min. 28 sec.
- Anytime Anywhere 2..
- 82%103 min. 56 sec.
@ Idols69.com - High definition AV Idol website...


text:
Software Map
Tag cloud | Project Tree | Project List
Project tree
Now limiting view to projects in the following categories:
Topic :: Database Administration :: Performance [Remove This Filter]
Development Status :: 4 - Beta [Remove This Filter]
Natural Language :: English [Remove This Filter]
Operating System > POSIX
Browse By:
1 project in result set.
|0. pgAutotune - Using a template postgresql.conf and test data, pgAutotune will run through a process of testing different settings on your PostgreSQL server and determine which settings have the best performance.
|Activity Percentile: 0.00
Activity Ranking: 0.00
Registered: 2004-04-26 20:00


text:
8,000 La Quinta Returns points for a free night stay.
Not a member? Join Now
Month of LoveExperience a romantic getaway with the one you love at the La Quinta Inn & Suites Danbury, ranked #1 of 15 Danbury, CT hotels on Tripadvisor!
Danbury Ice Arena PackageCalling all skating enthusiasts, exercise aficionados, and families looking for fun!
Outback Inn Steak PackageWe've teamed up with some good cookin' from our neighbors at The Outback!
Whalers PackageBreak the ice with our Danbury Whalers Hockey Date Night Package!
Grand Prix Stay and PlayGrand Prix New York is the ultimate escape for adults and kids alike!
Whether you're traveling on business, a leisure getaway, or a family vacation, La Quinta has the right hotel accommodations for you. Take advantage of free Internet access, free breakfast, and comfy beds offered at La Quinta Inns & Suites. You'll find the best rates online, the widest variety of room options, the most reliable hotel info, and more on LQ.com. Thank you for considering La Quinta Inns & Suites for your hotel travel plans!


text:
Lanz Cranberry Tyrolean Flannel Nightgown
Lanz of Salzburg's Beloved Tyrolean Print With a Different Look, Same Warm and Comfortable Style
Lanz Cranberry Tyrolean Flannel Nightgown
Lanz of Salzburg's Beloved Tyrolean Print With a Different Look, Same Warm and Comfortable Style
Adding regal medallions to the hearts and flowers and replacing the color scheme with rich cranberry on an ivory ground, Lanz of Salzburg's Cranberry Tyrolean nightgown is sure to be a cherished addition to your sleepwear collection. 100% cotton flannel nightgown , brushed for added softness, has button-front placket, gathered bodice, and relaxed fit. Signature Lanz eyelet trims the neck, yoke, and cuffs. Approx. 54" long. Machine wash and dry. Imported. Available in both Misses' and Women's sizes.
- 100% cotton flannel
- Button-front placket
- Eyelet details
The newest addition to the Lanz family of prints: Tyrolean in shades of cranberry and ivory.
Lanz Cranberry Tyrolean Flannel Nightgown
Fire warning inside all woven garments as per Federal Law.
100% Cotton
Machine wash cold gentle cycle with like colors. Use only non-chlorine bleach if needed and tumble dry low.
Manufactured In: China
Material - Country Of Origin: China
What Our Customers Are Saying about Our Lanz Cranberry Tyrolean Flannel Nightgown …
"Thank you for adding this beautiful new color to your Lanz collection. These are the best nightgown s ever. I always make a point to check out your Lanz offerings. I cannot say enough about their comfort and warmth. Thank you, Vermont Country Store!" - Sherry, Thomson, GA


text:
Read and Discuss
Have you checked with any electrical distributors in your area to see if they can
The isolation transformer needs to be sized for continuous input amps of the VFD. The
By clicking below, I acknowledge and agree to Penton's Terms of Service
and to Penton's use of my contact information to communicate with me about Penton's or its third-party
partners' products, services, events and research opportunities. Penton's use of the information I
provide will be consistent with Penton's Privacy Policy.
Sponsored Introduction Continue on to (or wait seconds) ×


text:
bus tweets
email: email@example.com
Your poem, on a bus
Calling all bus poets! Poetry on buses is back. This year's theme is "writing home." You can find submission guidelines here.
Bus cuts are coming
Thanks to the failure of our state legislature--and the subsequent failure of Prop 1 (aka, "plan B"), King County will lose 72 bus routes and see reduced service on over 100 more. There is a chance a plan will be cobbled together to save some service, but it will be even less ideal than the less-than-ideal plan that just failed.
Recent Posts
- Rider for life
- When "growing up" = getting behind the wheel
- Multimodal Monday: Sounder to the fair
- Rebelling by bus
- Westbound 27 stop, Yesler & 3rd, 8:15 AM
- On families and fares
- Summer of parks
- How to pass the time at a bus stop, part VII
- Car-free "vacation": Yakima
- Multimodal Monday: Link, then lake
In the Bus Bag
Children of the Days: A Calendar of Human History, by Eduardo Galeano
Monthly Archives: October 2012
Walking to pre-K, 8:15 AM
Chicklet, upon passing a photo of the President: "I wish the 578 would take us to Washington, DC."
10:19 pm Comments Offat
Category: busing with babies, multi-modal Tagged 578, Barack Obama, chicklet, out of the mouths of bus babes
Category: busing with babies, multi-modal Tagged 578, Barack Obama, chicklet, out of the mouths of bus babes


text:
The Nike Elite Jersey is constructed to the same specifications as the gear worn by the Bears' players on game day!
Enter full name. We'll ask for delivery information at checkout.
Woven laser cut jock tag
Tailored Fit designed for movement
Tagless neck label avoids irritation
There are currently no items in your shopping cart.
Your web browser's "cookie" feature must be enabled to use the shopping cart. If you added an item and received this message, it is possible the cookie is being blocked. Please adjust your browser's privacy settings to allow acceptance of 1st party cookies and try again.
Need Help? Call Customer Service: 866.805.8555
Shopping on a Phone or Tablet? View Mobile Site
Web Development by Americaneagle.com 2014


text:
Chinese Medicine for Fertility Menomonie WI
Menomonie, WI
Obstetrics & Gynecology
Menomonie, WI
Family Practice, Gynecology
Medical School: Baylor Coll Of Med, Houston Tx 77030
Graduation Year: 1971
Middleton, WI
In Vitro Fertilization (IVF)
Membership Organizations
Internet Health Resources
Appleton, WI
Affinity Medical Group OB/GYN
Obstetrics & Gynecology
Marshfield, WI
Obstetrics & Gynecology
Medical School: Univ Of Mn Med Sch-Minneapolis, Minneapolis Mn 55455
Graduation Year: 1993
Hospital: St Josephs Hospital, Marshfield, Wi
Group Practice: Marshfield Clinic; Ministry Health Care At Marshfield Clinic
Menomonie, WI
Obstetrics & Gynecology
Medical School: Univ Of Louisville Sch Of Med, Louisville Ky 40202
Graduation Year: 1969
Hospital: Middle Tennessee Med Ctr, Murfreesboro, Tn
Group Practice: Womans Clnc Of Murfreesboro
Menomonie, WI
Professional Memberships
Red Cedar Medical Center
Madison, WI
UW Health East Towne Clinic OB/GYN
Obstetrics & Gynecology
Waukesha, WI
Women's Ob/Gyn Care
Obstetrics & Gynecology
Milwaukee, WI
Obstetrics & Gynecology
Getting Pregnant Without Fertility Drugs
By Miki Shima, o.m.d.
Q: I've been trying to conceive for one year, so far unsuccessfully, and I'd like to avoid the hassle and expense of conventional fertility treatments. How effective is Chinese medicine alone in helping women get pregnant?
A: That depends on several factors. Your first step should be to see your gynecologist for a few exams. She can check for any physical obstructions that might be preventing pregnancy, such as a blockage in your fallopian tubes, and assess your levels of follicle stimulating hormone (FSH), which affects ovulation, to make sure you haven't entered early menopause. If your FSH levels are above 10, your chances of getting pregnant without any kind of conventional fertility treatment are very small; if you have high FSH levels and an obstruction, your chances are essentially zero.
However, if your FSH levels are 9 or below, and there are no physical obstructions, traditional Chinese medicine alone can substantially improve your odds. For instance, if you are between the ages of 35 and 40 and your FSH is around 9, you have about a 4 percent chance of getting pregnant without any treatment whatsoever; with acupuncture and Chinese herbs, I've found that the probability rises to about 25 percent.
If you do need to see an infertility doctor, Chinese medicine can still help. Many of my patients are women undergoing in vitro fertilization (IVF) or egg donation, and I've found that adding acupuncture, supplements, and herbs to the mix can raise their success rate by about 15 to 25 percent. One recent study from Germany reported that women who received a regular course of acupuncture immediately before and after in vitro fertilization were 58 percent more likely to get pregnant than those who underwent IVF alone.
Copyright 1999-2009 Natural Solutions: Vibrant Health, Balanced Living/Alternative Medicine/InnoVisi...